Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Genotype vs Clinically Guided Dosing of Warfarin to Prevent Adverse Events

Genotype vs Clinically Guided Dosing of Warfarin to Prevent Adverse Events Letters Table 2. Frequency of Clinical Process and Usability Issues Identified in the Possible Patient Harm Reports, 2013-2016 Usability Category, No. of Possible Patient Harm Events (%) System Clinical Availability Automation Workflow Processes Issues of Information Alerting and Defaults Data Entry Visual Display Interoperability Support Total Documentation 6 (1.1) 2 (0.4) 2 (0.4) 33 (5.9) 2 (0.4) 3 (0.5) 2 (0.4) 50 (9) b b Medication 13 (2.3) 77 (13.8) 22 (3.9) 44 (7.9) 22 (3.9) 19 (3.4) 10 (1.8) 207 (37.2) administration b b b Order placement 25 (4.5) 35 (6.3) 19 (3.4) 56 (10.1) 18 (3.2) 38 (6.8) 22 (3.9) 213 (38.2) Review of results 6 (1.1) 8 (1.4) 0 19 (3.4) 10 (1.8) 42 (7.5) 2 (0.4) 87 (15.6) Total 50 (9) 122 (21.9) 43 (7.7) 152 (27.3) 52 (9.3) 102 (18.3) 36 (6.5) 557 (100) Data were from the Pennsylvania Patient Safety Authority Database and a large multihospital academic health care system in the mid-Atlantic, outside of Pennsylvania. Value greater than 5%. Patient safety reports contain limited information mak- 2. International Organization for Standardization. ISO/IEC 25010:2011—Systems and software engineering—Systems and Software Quality Requirements ing it difficult to identify causal factors and may be subject to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Genotype vs Clinically Guided Dosing of Warfarin to Prevent Adverse Events

Han-You, Xu
JAMA , Volume 319 (12) – Mar 27, 2018
Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/genotype-vs-clinically-guided-dosing-of-warfarin-to-prevent-adverse-xxslMVt7hH

References (1)

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2018.0189
pmid
29584834
Publisher site
See Article on Publisher Site

Abstract

Letters Table 2. Frequency of Clinical Process and Usability Issues Identified in the Possible Patient Harm Reports, 2013-2016 Usability Category, No. of Possible Patient Harm Events (%) System Clinical Availability Automation Workflow Processes Issues of Information Alerting and Defaults Data Entry Visual Display Interoperability Support Total Documentation 6 (1.1) 2 (0.4) 2 (0.4) 33 (5.9) 2 (0.4) 3 (0.5) 2 (0.4) 50 (9) b b Medication 13 (2.3) 77 (13.8) 22 (3.9) 44 (7.9) 22 (3.9) 19 (3.4) 10 (1.8) 207 (37.2) administration b b b Order placement 25 (4.5) 35 (6.3) 19 (3.4) 56 (10.1) 18 (3.2) 38 (6.8) 22 (3.9) 213 (38.2) Review of results 6 (1.1) 8 (1.4) 0 19 (3.4) 10 (1.8) 42 (7.5) 2 (0.4) 87 (15.6) Total 50 (9) 122 (21.9) 43 (7.7) 152 (27.3) 52 (9.3) 102 (18.3) 36 (6.5) 557 (100) Data were from the Pennsylvania Patient Safety Authority Database and a large multihospital academic health care system in the mid-Atlantic, outside of Pennsylvania. Value greater than 5%. Patient safety reports contain limited information mak- 2. International Organization for Standardization. ISO/IEC 25010:2011—Systems and software engineering—Systems and Software Quality Requirements ing it difficult to identify causal factors and may be subject to

Journal

JAMA – American Medical Association

Published: Mar 27, 2018

There are no references for this article.